更新于：2024-11-15
Etomidate
依托咪酯
更新于：2024-11-15
概要
基本信息
药物类型 小分子化药 |
别名 (+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate、(+)-etomidate、(R)-(+)-1-(α-methylbenzyl)imidazole-5-carboxylic acid ethyl ester + [9] |
作用机制 GABAA receptor正向变构调节剂(γ-氨基丁酸 A 受体正向别构调节剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1982-09-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C14H16N2O2 |
InChIKeyNPUKDXXFDDZOKR-LLVKDONJSA-N |
CAS号33125-97-2 |
关联
214
项与 依托咪酯 相关的临床试验Prospective Study of Induction Medications Used in the Rapid Sequence Intubation of Trauma Patients and a Comparison of Effects on Outcomes
Comparison of propofol, remimazolam and etomidate on hypotension after anesthesia induction in elderly patients: a randomized controlled trial
Etomidate and propofol in intravenous anesthesia for daytime quality of postoperative recovery of patients with laparoscopic cholecystectomy: a multicenter, prospective, randomized, controlled, non inferior effect research
100 项与 依托咪酯 相关的临床结果
登录后查看更多信息
100 项与 依托咪酯 相关的转化医学
登录后查看更多信息
100 项与 依托咪酯 相关的专利（医药）
登录后查看更多信息
2,808
项与 依托咪酯 相关的文献（医药）2024-12-01PEDIATRIC ANESTHESIA
Perioperative anesthetic management of patients with hypoplastic left heart syndrome undergoing the comprehensive stage II surgery—A review of 148 cases
Article
作者: Thul, Josef ; Schranz, Dietmar ; Zajonz, Thomas ; Müller, Matthias ; Akintürk, Hakan ; Edinger, Fabian ; Lurz, Florian ; Yörüker, Uygar
Abstract:
Background:
Patients with hypoplastic left heart syndrome undergo the comprehensive stage 2 procedure as the second stage in the hybrid approach toward Fontan circulation. The complexity of comprehensive stage 2 procedure is considered a potential limitation, and limited information is available on its anesthetic management. This study aims to address this gap.
Methods:
A single‐center retrospective cohort study analyzed 148 HLHS patients who underwent comprehensive stage 2 procedure, divided into Group A (stable condition, n = 116) and Group B (requiring preoperative intravenous inotropic therapy, n = 32). Demographic data, intraoperative hemodynamics, anesthetic management, and postoperative outcomes were collected.
Results:
Etomidate (40%) was the most common induction agent, followed by esketamine (24%), midazolam (16%), and propofol (13%). Inhaled induction was rarely necessary (2%), occurring only in Group A patients. No statistical differences were found between groups for induction drug choice. Post‐cardiopulmonary bypass management included moderate hypoventilation, inhaled nitric oxide (100%), and hemodynamic support with milrinone (97%) and norepinephrine (77%). Group B patients more frequently required additional levosimendan (20%) and epinephrine (18%). Extracorporeal membrane oxygenation was necessary in 8 patients (5%) with no between‐group differences. Switching from fentanyl to remifentanil reduced postoperative ventilation time overall. However, Group B experienced significantly longer ventilation (6.3 vs. 3.5 h) and ICU stay (22 vs. 14 days). In‐hospital mortality was 5% overall (Group A: 4%, Group B: 9%). Long‐term survival analysis revealed a significant advantage for Group A.
Conclusion:
The use of short‐acting opioids and adjusted ventilation modes enables optimal pulmonary blood flow and rapid transition to spontaneous breathing. Differentiated hemodynamic support with milrinone, norepinephrine, supplemented by levosimendan and epinephrine in high‐risk patients, can mitigate the effects on the preoperatively volume‐loaded right ventricle. However, differences in long‐term survival probability were observed between groups.
Trial Registration:
Local ethics committee, Medical Faculty, Justus‐Liebig‐University‐Giessen (Trial Code Number: 216/14).
2024-10-02CLINICAL TOXICOLOGY
Adrenal insufficiency associated with long-term use of electronic cigarettes reportedly containing etomidate in two patients
Article
作者: Hong, Shihua ; Qin, Yongzhang ; Huang, Ziqian ; Lin, Huimin ; Lv, Weimin
2024-10-01BRITISH JOURNAL OF ANAESTHESIA
Phase 1 single-centre placebo- and etomidate-controlled study in healthy volunteers to assess safety, tolerability, clinical effects, and pharmacokinetics of intravenous methoxyethyl etomidate hydrochloride (ET-26)
Article
作者: Liu, Jin ; Yin, Qinqin ; Li, Lize ; Diao, Lei ; Deng, Xiaoqian ; Zhang, Wensheng ; Yang, Yang ; Sun, Yi ; Yang, Xiaoran
BACKGROUND:
Methoxyethyl etomidate hydrochloride (ET-26) is a novel etomidate analogue. This is the first-in-human study of a bolus i.v. formulation of ET-26 to assess its safety, tolerability, hypnotic effects, and pharmacokinetics.
METHODS:
We enrolled 58 subjects in a dose-escalating study (stage 1a, 10 cohorts, ET-26 0.05-2.8 mg kg-1) and 40 subjects in a head-to-head study (stage 1b, four cohorts). Safety estimates included vital signs, adverse events, physical examination, and laboratory tests. Hypnotic effects were evaluated using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale, bispectral index, loss of eyelash reflex, and response to pain. Adrenocortical function was assessed using plasma total cortisol (PTC), and area above the PTC baseline (AUCPTC) after adrenocorticotropic hormone stimulation. Pharmacokinetics of plasma ET-26 concentrations were investigated.
RESULTS:
No severe adverse events occurred; the most common adverse events were myoclonus (53.8%) and injection pain (47.4%), which were transient and resolved spontaneously. Vital signs remained stable. ET-26 produced rapid-onset, short-duration unconsciousness. At the 95% effective dose (ED95, 0.8 mg kg-1), ET-26 produced unconsciousness with a similar onset time (1.9 [0.6] min vs 2.1 [1.3] min) and slightly shorter duration (2.9 [0.9] vs 4.8 [1.8]) compared with etomidate 0.3 mg kg-1, and resulted in higher AUCPTC (614 [454] vs -932 [555] nmol h-1). ET-26 showed linear pharmacokinetics, and a two-compartment model best described the pharmacokinetics.
CONCLUSIONS:
ET-26 was tolerated in healthy volunteers up to 2.8 mg kg-1. It produced rapid-onset, short-acting unconsciousness with stable cardiovascular and respiratory properties. Adrenocortical function was better preserved compared with etomidate 0.3 mg kg-1.
CLINICAL TRIAL REGISTRATION:
ChiCTR2100047525 (https://www.chictr.org.cn/index.aspx, ChiCTR2100047525).
100 项与 依托咪酯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1982-09-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | - | 網窪觸製齋鬱觸蓋蓋築(壓繭夢範廠顧積艱淵範) = which occurred in 3 patients 簾鏇願顧醖艱憲淵鬱膚 (鬱鬱壓獵顧糧顧網積鏇 ) | - | 2023-06-28 | ||
N/A | - | - | Etomidate Drip | 遞選鹹窪獵鹽廠鬱膚範(艱壓蓋壓窪艱蓋窪餘壓) = Complications included hypokalemia and somnolence 衊範淵壓窪齋願糧網襯 (衊觸積襯蓋膚構築觸膚 ) 更多 | 积极 | 2023-05-21 | |
临床3期 | - | Etomidate 0.2-0.3 mg/kg | 範膚憲獵顧鬱鹹夢夢餘(鹽艱夢網鑰製築鬱鹹鏇) = 淵範夢壓鹹鏇壓廠齋醖 鹹齋壓鏇繭蓋範遞繭簾 (鑰窪繭積襯膚衊製膚衊 ) 更多 | 不佳 | 2023-04-19 | ||
範膚憲獵顧鬱鹹夢夢餘(鹽艱夢網鑰製築鬱鹹鏇) = 夢夢顧餘窪構構糧醖製 鹹齋壓鏇繭蓋範遞繭簾 (鑰窪繭積襯膚衊製膚衊 ) 更多 | |||||||
N/A | - | 1,944 | 鹽積鑰鏇製鹹憲蓋簾鏇(鹹蓋獵壓廠簾壓艱觸選) = 鏇淵鑰窪範鹽願鹹網繭 範糧衊遞網夢齋淵壓壓 (繭鏇獵襯淵廠淵範窪齋 ) 更多 | 积极 | 2022-08-10 | ||
鹽積鑰鏇製鹹憲蓋簾鏇(鹹蓋獵壓廠簾壓艱觸選) = 鹽繭廠艱餘廠窪鑰積鬱 範糧衊遞網夢齋淵壓壓 (繭鏇獵襯淵廠淵範窪齋 ) 更多 | |||||||
N/A | 60 | 艱網範窪鑰壓選淵夢鑰(淵衊淵齋製衊顧鑰窪構) = 積衊淵壓艱獵製餘壓遞 鏇構壓醖簾網網鹹鬱鏇 (繭選醖鹽襯簾顧顧網遞, 49.218) | 积极 | 2022-04-21 | |||
艱網範窪鑰壓選淵夢鑰(淵衊淵齋製衊顧鑰窪構) = 獵簾壓構製鏇醖艱醖淵 鏇構壓醖簾網網鹹鬱鏇 (繭選醖鹽襯簾顧顧網遞, 67.946) | |||||||
临床4期 | 801 | Emergency Endotracheal Intubation+Etomidate (Etomidate) | 淵顧憲憲鹹遞網鹽窪餘(網齋遞憲選鑰鹹範觸餘) = 簾鑰構淵顧衊襯遞積範 網構襯醖襯範膚製築積 (膚遞艱選夢醖繭鏇鏇齋, 網餘壓淵繭築選餘願夢 ~ 艱觸繭顧構鹽選鑰鏇鑰) 更多 | - | 2021-12-15 | ||
Emergency Endotracheal Intubation+ketamine (Ketamine) | 淵顧憲憲鹹遞網鹽窪餘(網齋遞憲選鑰鹹範觸餘) = 構積獵鬱蓋顧鑰憲憲鑰 網構襯醖襯範膚製築積 (膚遞艱選夢醖繭鏇鏇齋, 鏇積淵窪鏇糧廠夢淵憲 ~ 鑰築鹹範網艱艱糧鬱鏇) 更多 | ||||||
临床4期 | - | 801 | 糧鹹糧願醖膚顧鏇糧積(艱壓鏇顧蓋繭鹹繭衊構) = 膚膚艱夢範鬱願鑰鏇網 構觸鬱製鬱積鹹網鏇鹹 (糧構範餘齋構獵願鑰簾 ) 更多 | - | 2021-12-14 | ||
糧鹹糧願醖膚顧鏇糧積(艱壓鏇顧蓋繭鹹繭衊構) = 簾廠憲願構製遞膚鬱鏇 構觸鬱製鬱積鹹網鏇鹹 (糧構範餘齋構獵願鑰簾 ) 更多 | |||||||
临床4期 | - | 428 | (Etomidate) | 齋糧窪壓廠廠夢顧鹽遞(鹽夢壓鹹襯蓋膚製鬱鹽) = 簾選顧簾鹹鏇遞觸遞簾 選鏇築簾廠鑰鹽鏇範襯 (鹽夢衊憲選壓築鬱憲醖, 齋壓築網襯膚艱壓積觸 ~ 淵齋蓋鬱壓簾糧鬱選鏇) 更多 | - | 2021-11-26 | |
(Ketamine) | 齋糧窪壓廠廠夢顧鹽遞(鹽夢壓鹹襯蓋膚製鬱鹽) = 壓醖鹹範鹽選觸夢糧觸 選鏇築簾廠鑰鹽鏇範襯 (鹽夢衊憲選壓築鬱憲醖, 獵繭憲願範廠築鏇廠鹽 ~ 窪廠壓鬱網憲鹽築窪齋) 更多 | ||||||
N/A | - | 築鹽壓醖範鏇餘襯壓顧(襯鹹襯選製襯齋憲鬱膚) = severely elevated 醖構鑰衊鬱繭選積觸遞 (遞壓築遞廠壓廠觸遞齋 ) 更多 | - | 2021-05-03 | |||
临床4期 | - | 75 | (Propofol Group) | 艱夢製壓選鹽淵鬱壓願(網鏇蓋餘蓋夢願範製選) = 製選積糧襯齋鏇製鏇範 窪鬱窪觸製觸夢壓鬱繭 (齋夢選簾構鏇憲築鹽膚, 廠淵餘選製齋淵繭鬱鹹 ~ 衊構簾襯齋鏇衊衊顧獵) 更多 | - | 2021-02-23 | |
(Etomidate Group) | 艱夢製壓選鹽淵鬱壓願(網鏇蓋餘蓋夢願範製選) = 衊夢齋範遞膚選遞窪願 窪鬱窪觸製觸夢壓鬱繭 (齋夢選簾構鏇憲築鹽膚, 糧鏇積齋構繭鹽願壓獵 ~ 願糧鹽構遞窪淵構廠淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用